Standard of care of carcinomas on cancer of unknown primary site in 2016

Marc Antoine Benderra; Marius Ilié; Paul Hofman; Christophe Massard

doi:10.1016/j.bulcan.2016.05.003

Standard of care of carcinomas on cancer of unknown primary site in 2016

Titre traduit de la contribution: Prise en charge des carcinomes de primitif inconnu en 2016

Marc Antoine Benderra, Marius Ilié, Paul Hofman, Christophe Massard

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

11 Citations (Scopus)

Résumé

Patients with Cancer of unknown primary (cup) represent 2–10%, and have disseminated cancers for which we cannot find the primary site despite the clinical, pathological and radiological exams at our disposal. Diagnosis is based on a thorough clinical and histopathologic examination as well as new imaging techniques. Several clinicopathologic entities requiring specific treatment can be identified. Genome sequencing and liquid biopsy (circulating tumor cells and tumor free DNA) could allow further advances in the diagnosis. Therapeutically, in addition to surgery, radiotherapy and chemotherapy, precision medicine provides new therapeutic approaches.

Titre traduit de la contribution	Prise en charge des carcinomes de primitif inconnu en 2016
langue originale	Anglais
Pages (de - à)	697-705
Nombre de pages	9
journal	Bulletin du Cancer
Volume	103
Numéro de publication	7-8
Les DOIs	https://doi.org/10.1016/j.bulcan.2016.05.003
état	Publié - 1 juil. 2016

Accès au document

10.1016/j.bulcan.2016.05.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{08ea1781446742d692a1f58c1eeeaf61,

title = "Standard of care of carcinomas on cancer of unknown primary site in 2016",

abstract = "Patients with Cancer of unknown primary (cup) represent 2–10%, and have disseminated cancers for which we cannot find the primary site despite the clinical, pathological and radiological exams at our disposal. Diagnosis is based on a thorough clinical and histopathologic examination as well as new imaging techniques. Several clinicopathologic entities requiring specific treatment can be identified. Genome sequencing and liquid biopsy (circulating tumor cells and tumor free DNA) could allow further advances in the diagnosis. Therapeutically, in addition to surgery, radiotherapy and chemotherapy, precision medicine provides new therapeutic approaches.",

keywords = "Cancer of unknown primary, Chemotherapy, Genome sequencing, Immunohistochemistry, Liquid biopsy, Precision medicine",

author = "Benderra, {Marc Antoine} and Marius Ili{\'e} and Paul Hofman and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2016 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.bulcan.2016.05.003",

language = "English",

volume = "103",

pages = "697--705",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "7-8",

}

TY - JOUR

T1 - Standard of care of carcinomas on cancer of unknown primary site in 2016

AU - Benderra, Marc Antoine

AU - Ilié, Marius

AU - Hofman, Paul

AU - Massard, Christophe

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Patients with Cancer of unknown primary (cup) represent 2–10%, and have disseminated cancers for which we cannot find the primary site despite the clinical, pathological and radiological exams at our disposal. Diagnosis is based on a thorough clinical and histopathologic examination as well as new imaging techniques. Several clinicopathologic entities requiring specific treatment can be identified. Genome sequencing and liquid biopsy (circulating tumor cells and tumor free DNA) could allow further advances in the diagnosis. Therapeutically, in addition to surgery, radiotherapy and chemotherapy, precision medicine provides new therapeutic approaches.

AB - Patients with Cancer of unknown primary (cup) represent 2–10%, and have disseminated cancers for which we cannot find the primary site despite the clinical, pathological and radiological exams at our disposal. Diagnosis is based on a thorough clinical and histopathologic examination as well as new imaging techniques. Several clinicopathologic entities requiring specific treatment can be identified. Genome sequencing and liquid biopsy (circulating tumor cells and tumor free DNA) could allow further advances in the diagnosis. Therapeutically, in addition to surgery, radiotherapy and chemotherapy, precision medicine provides new therapeutic approaches.

KW - Cancer of unknown primary

KW - Chemotherapy

KW - Genome sequencing

KW - Immunohistochemistry

KW - Liquid biopsy

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=84977622837&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2016.05.003

DO - 10.1016/j.bulcan.2016.05.003

M3 - Short survey

C2 - 27372228

AN - SCOPUS:84977622837

SN - 0007-4551

VL - 103

SP - 697

EP - 705

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 7-8

ER -